MIRA PharmaceuticalsMIRA
About: Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
Employees: 6
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
53% more funds holding
Funds holding: 15 [Q3] → 23 (+8) [Q4]
18% more capital invested
Capital invested by funds: $1.08M [Q3] → $1.28M (+$197K) [Q4]
1.15% more ownership
Funds ownership: 5.62% [Q3] → 6.76% (+1.15%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for MIRA.
Financial journalist opinion









